The legacy success of Viagra has undeniably shaped the drug landscape. However, investing in companies heavily dependent on biosimilars and the declining patent exclusivity surrounding this flagship https://linkedbookmarker.com/story7004153/the-blue-pill-and-pharmaceutical-companies-a-risky-opportunity